Sun Pharma Launches SEZABY™ in the U.S. for Treatment of Neonatal Seizures

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) has announced the launch of SEZABY™ (phenobarbital sodium) in the U.S. for the treatment of neonatal seizures. SEZABY is the first and only product approved by the U.S. Food and Drug Administration (US FDA) for the treatment of neonatal seizures in term and preterm infants.

SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection. It was granted orphan drug designation by the US FDA for the treatment of neonatal seizures.

"The launch of SEZABY is an exciting addition to our growing portfolio of specialty branded products in the U.S.," said Abhay Gandhi, CEO North America, Sun Pharma. "As the first and only FDA-approved product for the treatment of seizures in term and preterm infants, SEZABY has the potential to make a meaningful difference in the lives of patients and their families, and we are proud to be able to provide physicians with this new treatment option."

Shares of Sun Pharmaceutical Industries Limited was last trading in BSE at Rs. 1039.95 as compared to the previous close of Rs. 1041.00. The total number of shares traded during the day was 34221 in over 3613 trades.

The stock hit an intraday high of Rs. 1045.00 and intraday low of 1028.05. The net turnover during the day was Rs. 35442110.00.

Source : Equity Bulls

Keywords

SunPharmaceuticalIndustries INE044A01036 SEZABY PhenobarbitalSodium US Launch NeonatalSeizures